Europe Subcutaneous Immunoglobulin Market Size, Share, Trends, Industry Analysis Report By Product (IgG, IgA, IgM), By Application, By End Use, By Country – Market Forecast, 2025–2034
Description
The Europe Subcutaneous Immunoglobulin Market size is expected to reach USD 5.9 billion by 2034, according to a new study by Polaris Market Research. The report “Europe Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report By Product (IgG, IgA, IgM), By Application, By End Use, By Country; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Subcutaneous immunoglobulin (SCIG) is a method of antibody replacement therapy that enables consistent immune protection through regular administration under the skin. The European market is witnessing a growing shift toward home-based care, as SCIG offers patients greater flexibility and independence compared to hospital-based intravenous therapies. This trend is further reinforced by rising demand for patient-centric treatment approaches that reduce hospital visits, enhance quality of life, and ensure long-term disease management. The convenience and safety profile of SCIG have positioned it as a preferred therapy, aligning with the broader movement toward decentralized healthcare delivery.
The Europe SCIG market growth is driven by the continuous innovation in drug formulations and drug delivery devices, which is making treatment more accessible and efficient for patients. Advancements such as higher-concentration formulations, reduced infusion times, and user-friendly infusion technologies are improving treatment adherence and patient satisfaction. These innovations simplify administration and also support the goal of long-term, sustainable immunoglobulin therapy by minimizing the physical and psychological burden of treatment. Together, these developments highlight the evolving landscape of SCIG, where technology and patient needs are shaping the future of immune replacement therapy.
Europe Subcutaneous Immunoglobulin (SCIG) Market Report Highlights
In terms of product, the IgG segment dominated the market in 2024 due to its critical role in providing effective immune protection for a wide range of immunodeficiency disorders.
Based on application, the secondary immunodeficiency segment is expected to witness significant growth driven by the rising prevalence of chronic illnesses and immunosuppressive treatments, such as chemotherapy.
Based on end use, the hospitals segment held the largest share in 2024 as the primary center for initial treatment, complex case management, and patient monitoring.
The market in Germany is expected to witness significant growth, driven by its robust healthcare infrastructure and strong focus on advancing immunology treatment options.
The UK market is expanding due to increasing awareness of immunodeficiency disorders and a national healthcare system that focuses on patient-centered care models.
A few key players in the Europe subcutaneous immunoglobulin market include ADMA Biologics, Inc.; Baxter International Inc.; Biotest AG; CSL Behring; Grifols S.A.; Johnson & Johnson (Omrix Biopharmaceuticals Inc.); Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Shanghai RAAS Blood Products Co. Ltd.; and Takeda Pharmaceutical Company Limited.
Polaris Market Research has segmented the market report on the basis of product type, application, end use, and country:
By Product Type Outlook (Revenue, USD Billion, 2020–2034)
IgG
IgA
IgM
By Application Outlook (Revenue, USD Billion, 2020–2034)
Primary Immunodeficiency Disease
Secondary Immunodeficiency Disease
By End Use (Revenue, USD Billion, 2020–2034)
Hospitals
Homecare
Clinics
Others
By Country (Revenue, USD Billion, 2020–2034)
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Subcutaneous immunoglobulin (SCIG) is a method of antibody replacement therapy that enables consistent immune protection through regular administration under the skin. The European market is witnessing a growing shift toward home-based care, as SCIG offers patients greater flexibility and independence compared to hospital-based intravenous therapies. This trend is further reinforced by rising demand for patient-centric treatment approaches that reduce hospital visits, enhance quality of life, and ensure long-term disease management. The convenience and safety profile of SCIG have positioned it as a preferred therapy, aligning with the broader movement toward decentralized healthcare delivery.
The Europe SCIG market growth is driven by the continuous innovation in drug formulations and drug delivery devices, which is making treatment more accessible and efficient for patients. Advancements such as higher-concentration formulations, reduced infusion times, and user-friendly infusion technologies are improving treatment adherence and patient satisfaction. These innovations simplify administration and also support the goal of long-term, sustainable immunoglobulin therapy by minimizing the physical and psychological burden of treatment. Together, these developments highlight the evolving landscape of SCIG, where technology and patient needs are shaping the future of immune replacement therapy.
Europe Subcutaneous Immunoglobulin (SCIG) Market Report Highlights
In terms of product, the IgG segment dominated the market in 2024 due to its critical role in providing effective immune protection for a wide range of immunodeficiency disorders.
Based on application, the secondary immunodeficiency segment is expected to witness significant growth driven by the rising prevalence of chronic illnesses and immunosuppressive treatments, such as chemotherapy.
Based on end use, the hospitals segment held the largest share in 2024 as the primary center for initial treatment, complex case management, and patient monitoring.
The market in Germany is expected to witness significant growth, driven by its robust healthcare infrastructure and strong focus on advancing immunology treatment options.
The UK market is expanding due to increasing awareness of immunodeficiency disorders and a national healthcare system that focuses on patient-centered care models.
A few key players in the Europe subcutaneous immunoglobulin market include ADMA Biologics, Inc.; Baxter International Inc.; Biotest AG; CSL Behring; Grifols S.A.; Johnson & Johnson (Omrix Biopharmaceuticals Inc.); Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Shanghai RAAS Blood Products Co. Ltd.; and Takeda Pharmaceutical Company Limited.
Polaris Market Research has segmented the market report on the basis of product type, application, end use, and country:
By Product Type Outlook (Revenue, USD Billion, 2020–2034)
IgG
IgA
IgM
By Application Outlook (Revenue, USD Billion, 2020–2034)
Primary Immunodeficiency Disease
Secondary Immunodeficiency Disease
By End Use (Revenue, USD Billion, 2020–2034)
Hospitals
Homecare
Clinics
Others
By Country (Revenue, USD Billion, 2020–2034)
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. U.S. Subcutaneous Immunoglobulin Market Insights
- 4.1. U.S. Subcutaneous Immunoglobulin Market – Market Snapshot
- 4.2. U.S. Subcutaneous Immunoglobulin Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Patient Preference for Home-Based Care
- 4.2.1.2. Rising Prevalence of Neurological and Autoimmune Diseases
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost of treatment and limited plasma supply
- 4.2.3. Public opinion and privacy legal precedents
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. U.S. Subcutaneous Immunoglobulin Market Trends
- 4.6. Value Chain Analysis
- 5. U.S. Subcutaneous Immunoglobulin Market, By Product Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Subcutaneous Immunoglobulin Market, By Product Type, 2020–2034 (USD Billion)
- 5.3. IgG
- 5.3.1. U.S. Subcutaneous Immunoglobulin Market, by IgG, 2020–2034 (USD Billion)
- 5.4. IgA
- 5.4.1. U.S. Subcutaneous Immunoglobulin Market, by IgA, 2020–2034 (USD Billion)
- 5.5. IgM
- 5.5.1. U.S. Subcutaneous Immunoglobulin Market, by IgM, 2020–2034 (USD Billion)
- 6. U.S. Subcutaneous Immunoglobulin Market, By Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Subcutaneous Immunoglobulin Market, By Application, 2020–2034 (USD Billion)
- 6.3. Primary Immunodeficiency Disease
- 6.3.1. U.S. Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, 2020–2034 (USD Billion)
- 6.4. Secondary Immunodeficiency Disease
- 6.4.1. U.S. Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, 2020–2034 (USD Billion)
- 7. U.S. Subcutaneous Immunoglobulin Market, By End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Subcutaneous Immunoglobulin Market, By End Use, 2020–2034 (USD Billion)
- 7.3. Hospitals
- 7.3.1. U.S. Subcutaneous Immunoglobulin Market, by Hospitals, 2020–2034 (USD Billion)
- 7.4. Homecare
- 7.4.1. U.S. Subcutaneous Immunoglobulin Market, by Homecare, 2020–2034 (USD Billion)
- 7.5. Clinics
- 7.5.1. U.S. Subcutaneous Immunoglobulin Market, by Clinics, 2020–2034 (USD Billion)
- 7.6. Others
- 7.6.1. U.S. Subcutaneous Immunoglobulin Market, by Others, 2020–2034 (USD Billion)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. ADMA Biologics, Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Baxter International Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Biotest AG
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. CSL Behring
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Grifols S.A.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Johnson & Johnson (Omrix Biopharmaceuticals Inc.)
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Kedrion S.p.A
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Octapharma AG
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Pfizer Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Shanghai RAAS Blood Products Co. Ltd.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Takeda Pharmaceutical Company Limited
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.